Status: Recruiting
A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
This study is a 3-part, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamic properties of iN1011-N17 after Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia patients, and to assess the relative bioavailability of Mesylate vs Hydrochloride salt capsules of iN1011-N17 in Healthy volunteers.
Participants needed: 64
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: iN Therapeutics Co., Ltd.Updated: Jun 24, 2024Locations: 1
Eligibility criteria
Healthy male and female adults, aged 18 to 55 years of age (inclusive) at the ti... [+13]
Presence or history of carcinoma, hepatic, renal, neurological, pulmonary (excep... [+32]